Australasian Business Intelligence - Ramipril reduces cardiac risk in normotensives.
Apr 10, 2002 (Pharmacy News
Related Results
RAMIPRIL.Sandoz launches ramiprilCutaneous vasculitis secondary to ramiprilRamipril cuts diabetes riskRamipril-associated hepatotoxicity
ABIX via COMTEX) -- The landmark HOPE trial shows that normotensive patients on ramipril 10mg have reduced risks of stroke, heart attacks and deaths. An analysis of the European study also shows that the reduction in risk of the cardiovascular events were three times more than expected from the drug’s blood pressure-lowering effects on the overall trial participants. The manufacturer of ramipril, Aventis Pharma, says the research suggests that ramipril 10mg might have additional, but unknown, properties, which prevent cardiovascular events in victims …
Read the rest of this article with a Free Trial at HighBeam Research.
